Company news
Coherus Oncology, Inc. news in 2024
Coherus Oncology, Inc.'s news releases, calls and decks from 2024, newest first.
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
December 17, 2024
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 2, 2024
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 5, 2024
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
July 31, 2024
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 26, 2024
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
June 4, 2024
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 8, 2024
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 7, 2024
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
April 30, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2024
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 12, 2024
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 4, 2024
Coherus Completes Divestiture of Ophthalmology Franchise
March 3, 2024
Coherus BioSciences Announces New Employment Inducement Grants
February 22, 2024
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
February 20, 2024
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 4, 2024
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
January 21, 2024
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 17, 2024
Coherus Announces U.S. Launch of LOQTORZI™
January 1, 2024